Trials / Completed
CompletedNCT02389413
Safety and Tolerability of PQ912 in Subjects With Early Alzheimer's Disease
A Phase 2A Multicentre, Randomised, Double Blind, Placebo-Controlled, Parallel-Group Safety and Tolerability Study of PQ912 in Subjects With Early Alzheimer's Disease
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 120 (actual)
- Sponsor
- Vivoryon Therapeutics N.V. · Industry
- Sex
- All
- Age
- 50 Years – 89 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the safety, tolerability and preliminary efficacy of PQ912 in subjects with Mild Cognitive Impairment (MCI) due to Alzheimers Disease (AD) or mild dementia due to AD.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PQ912 oral | |
| OTHER | Placebo |
Timeline
- Start date
- 2015-03-01
- Primary completion
- 2017-04-01
- Completion
- 2017-04-01
- First posted
- 2015-03-17
- Last updated
- 2017-06-01
Locations
23 sites across 7 countries: Belgium, Finland, France, Germany, Netherlands, Spain, Sweden
Source: ClinicalTrials.gov record NCT02389413. Inclusion in this directory is not an endorsement.